Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic Window

The metabotropic glutamate receptor subtype 5 (mGluR5) is heavily implicated in the neural circuitry of addiction, showing altered binding in human imaging studies of individuals with drug and nicotine dependence. This systematic review evaluated whether negative allosteric modulators (NAMs) of mGluR5—specifically MTEP and MPEP—demonstrate therapeutic potential for treating addiction. The authors analyzed preclinical data from studies on rats, mice, and monkeys to determine if these compounds satisfy three criteria: reliable suppression of addiction-like behaviors, a predictable dose-response relationship, and a distinct therapeutic window where drug seeking is inhibited without disrupting responses to natural reinforcers like food.

The analysis revealed that both MTEP and MPEP reliably suppress self-administration and reinstatement behaviors related to cocaine, ethanol, and nicotine. The researchers identified a consistent, sigmoidal dose-response relationship across these substances. Notably, a therapeutic window exists at doses producing approximately 50% to 80% mGluR5 occupancy. Within this range, the compounds significantly inhibited drug-related behaviors while having little to no impact on food self-administration. This effect remained robust regardless of whether the animals were food-restricted or had ad libitum access. Preliminary data from mice and monkeys supported these findings, suggesting the therapeutic window may be translatable across species.

The identification of a consistent therapeutic window suggests that mGluR5 NAMs could target a final common pathway in addiction, rather than acting on the specific primary binding sites of various drugs. While MTEP and MPEP possess pharmacokinetic limitations and off-target effects that complicate immediate clinical application, the results provide a strong rationale for developing more selective and clinically viable mGluR5 modulators. The authors argue that future clinical studies should prioritize dosage ranges that achieve the identified 50% to 80% occupancy threshold, focusing on disorders characterized by compulsive behavior.